Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• This invention relates to the field of nanoparticles and, more specifically, to cellulose- based nanoparticles for drug delivery.
• polymeric therapeutics 1 "2 In the field of controlled drug delivery, the use of polymers to enhance solubility, pharmacodynamics (PK), pharmacodynamics (PD), bioavailability, efficacy, and decrease systemic toxicity is largely defined as polymeric therapeutics 1 "2 .
• the generalized model of polymer therapeutics is attributed to Ringsdorf 3 , a model he proposed in 1975, wherein a polymer architecture is modified by solubilizers, drugs, and disease targeting ligands to more effectively dissolve hydrophobic drugs and delivery them in a focused manner.
• particles can be functionalized with targeting ligands to promote the cellular internalization of nanoparticles to specific tissues over- expressing specific receptors, such as folate 32 , RGD 33 and HER2 34 .
• targeting ligands can increase the blood clearance of the particles, 36"37 and that particles internalized though receptor recognition are trapped in the endosome/lysosome organelles and drug is often degraded.
• Imaging contrast agents into nanoparticles to enable realtime visualization of the particle (and drug) distribution in the physiology, permitting sensitive non-destructive measurement of biodistribution, and giving rise the field of personalized medicine and theranostics.
• SPIONS superparamagnetic iron oxide nanoparticles
• Liposomes and polymeric micelles can be loaded with gadolinium compounds, which like SPIONS, provide MRI contrast.
• Polymers can also be labeled with tracers such as " 'indium for microSPECT analysis, 43 or with dyes such as Cy5.5 for fluorescence imaging 44
• hydrophobic drugs such as paclitaxel (PTX) can be loaded non-covalently in the core of micelle-forming polymers.
• PEG-PLA micelles Genexol, now in Phase II clinical trials
• NK105 a PEG-aspartic acid formulation 45
• Genexol and NK105 PTX micelle formulations improve upon administration of PTX alone, by reducing formulation toxicity through elimination of the Cremophor-based PTX delivery vehicle which causes hypersensitivity issues in human patients.
• Opaxio also known as Xyotax and Polyglumex
• Opaxio is in Phase III clinical trials, and to date, represents a promising candidate for approval.
• PTX free drug
• NK105 micelle
• Genexol micelle
• Opaxio conjugate
• the half lives were 13.3, 10.6, 1 1.4, and 120 hours respectively, for doses of 210, 150, 300, and 233 mg/m 2 .
• the PK profile of the non-covalent NK105 and Genexol formulations were nearly identical to that of free PTX, whereas the Opaxio polymer conjugate was the only mode by which PK could be substantially improved.
• Hydrophobic drugs such as PTX and docetaxel (DTX) will partition from the micelle to plasma proteins including albumin and alpha- 1 -acid glycoprotein, rapidly depleting the nanoparticle of the drug content. 46 Therefore, dramatic improvements to PK and efficacy are likely to be seen only with polymer conjugates.
• a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug comprising a taxane, preferably cabazitaxel or larotaxel.
• CMC-Ac acetylated carboxymethylcellulose
• a self-assembling nanoparticle composition comprising the compound described herein.
• the composition has a critical micelle concentration (cmc) of about 0.1 mg/mL.
• a pharmaceutical composition comprising the self-assembling nanoparticle composition described herein and a pharmaceutically acceptable carrier and/or diluent.
• a method for providing sustained-release delivery of a hydrophobic drug to a patient in need thereof comprising administering to the patient an effective amount of the self-assembling nanoparticle composition as described.
• a method of treating cancer in a patient in need thereof comprising administering to said patient an effective amount of a self-assembling nanoparticle composition comprising the compound described herein.
• the cancer is selected from breast cancer, lung cancer, metastatic cancer, and pancreatic cancer.
• a process for preparing a self-assembling nanoparticle composition comprising: a) covalently linking at least one PEG and at least one hydrophobic drug to a CMC- Ac; b) isolating the product of step (a); c) dissolving the isolated product of step (b) in a suitable organic solvent, preferably DMF or DMSO and further preferably THF or acetonitrile, to form a solution; d) adding the solution of step (c) dropwise or by nanoprecipitation processes to an aqueous solution under conditions suitable for forming the self-assembling nanoparticle composition; the hydrophobic drug comprising a taxane, preferably cabazitaxel or larotaxel.
• Ri ( i)...Ri (n ), R 2 (i)...R 2 ( n ), R 3( i)...R3( n ), and Rend are each independently selected from:
• n is an integer > 94;
• the hydrophobic drug comprising a taxane, preferably cabazitaxel or larotaxel BRIEF DESCRIPTION OF THE DRAWINGS
• Figure 1 shows a schematic of a polymer conjugate according to one aspect, wherein Ro, Ri( i)...Ri (n), R 2 (i)...R 2 (n)» R3(i)...R3(n)> and Rend are each independently selected from:
• Figure 2 shows the ⁇ NMR of Cellax-DTX and Components.
• A Spectra of DTX, sodium carboxymethylcellulose (CMC-Na), acetylated CMC, and the Cellax-DTX product.
• B DTX with the carbon numbering scheme.
• FIG. 3 shows (A) Analysis of Tl and T2 signal for Cellax-DTX-SPIONS in vitro. MRI analysis of mice bearing EMT-6 flank tumors, and treated with Cellax-DTX- SPION (10 mg Fe/kg, 133 mg/kg DTX).
• B Pre-injection T2* scan
• C pre-injection T2 scan
• D 3-hour post-injection T2* scan
• E 3-hour post-injection T2 scan.
• the tumor volume can be differentiated from the neighboring tissues in the background scans, and substantial development of MR contrast due to the SPION susceptibility artifact.
• F calculation of hypointense volume fractions by MIPAV image analysis, wherein hypointense voxels are defined as having an intensity below that of 5 SD standard deviation of the mean intensity of neighboring muscle.
• Figure 4 shows the release of DTX from Cellax-DTX particles in FBS containing saline (50 vol%). Particles were incubated at 37°C in a 5% CO 2 atmosphere. At selected timepoints samples were extracted and analyzed by HPLC. Two peaks were detected: DTX and 7-epidocetaxol. Total taxanes in the plot refers to the combined release of DTX and the isomer, and indicates when full release had been reached.
• Figure 5 shows the IC50 analysis of DTX toxicity.
• Figure 6 shows the toxicity assay (maximum tolerated dose) analysis of DTX and Cellax-DTX in Balb/c mice. Healthy tumor-free mice were injected with DTX (in a Tween80/ethanol/saline 20: 13:67 carrier) or Cellax-DTX (0.9% saline). Body weight was measured regularly, and the limiting toxic dose was set by ⁇ 5% body weight loss. Cellax-DTX reaches a maximum concentration of 15 mg/mL DTX (170 mg/kg), so a true MTD is not known.
• Figure 7 shows the efficacy of the DTX and Cellax-DTX treatments on mice carrying syngeneic flank tumors.
• DTX was formulated in Tween80/ethanol/saline
• Cellax- DTX was formulated in 0.9% saline.
• Control mice were treated with saline.
• Figure 8A shows the histological and immunohistological analysis of EMT-6 tumors in Balb/c mice.
• Left column control mice.
• Middle column DTX (40 mg/kg) treated mice.
• Right column Cellax-DTX (40 mg DTX/kg) treated mice.
• TUNEL staining 40X: indication of apoptosis is evident in all samples, but is markedly greater in the Cellax-DTX-treated tumor, and the morphology of the stained regions is similar to the necrotic regions in the H&E stained sections.
• Ki67 staining regions of the DTX and Cellax-DTX treated tumors are devoid of cell replication events, and these regions are congruent to the H&E and TU EL images.
• Figure 8B shows the immunohistological analysis of the kidney and lungs of Balb/c mice (carrying EMT-6 flank tumors) treated with saline, DTX (40 mg/kg) and Cellax- DTX (40 mg DTX/kg). Images are 400X magnification. Note the presence of positive TUNEL staining in the DTX-treated mice, and the absence of staining in control and Cellax-DTX-treated mice.
• Figure 9 shows tumor histology: quantification of stains
• A Hemotoxylin staining of tumors
• B TUNEL staining of tumors
• C Ki67 staining of tumors
• D CD31 staining of tumors
• E TUNEL staining in kidneys
• F TUNEL staining in lungs.
• Figure 10 shows tumor histology for the LL/2 model in C57/BL6 mice: (A) H&E staining, (B) TUNEL staining.
• Figure 12 shows survival patterns in C57/BL6 mice inoculated with PAN02 murine pancreatic cells (2.5 x 10 6 cell/injection).
• Figure 13 shows tumor inhibition responses in NOD-SCID mice inoculated with (a) PC3 prostate cells or (b) DTX-resistant PC3 prostate cells.
• PC3 model only Cellax-CBZ induced a durable remission.
• DTX-resistant PC3 model no inhibition was observed with CBZ treatment, but Cellax-CBZ induced a significant inhibition.
• a functional polymeric nanoparticle preferably comprises the following attributes: (1) it dissolves or transports a hydrophobic drug in an aqueous environment, (2) the drug is protected from metabolism by the particle, (3) the particle is protected from RES elimination by PEG or other suitable chemistry, (4) the polymer self-assembles into a suitably scaled nanoparticle due to a balance in hydrophobic and hydrophilic elements, (5) the particle accumulates in the targeted disease compartment through passive accumulation (6) the link between the drug and particle is reversible, so that the drug can be released and (7) the polymer is biocompatible , and (8) the particle contains an agent to provide imaging contrast or detection in the physiological system.
• One objective was to engineer a cellulose-based composition to deliver a hydrophobic drug, preferably DTX, the design of which would preferably address the major design elements described above.
• a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug comprising a taxane, preferably cabazitaxel or larotaxel.
• the covalent linkages are ester linkages.
• each of the hydrophobic drug and PEG may be covalently linked to the CMC-Ac by a direct linkage between a carboxylic acid residue of the CMC -Ac and a functional group of the hydrophobic drug and PEG (e.g. a hydroxyl group), or by an indirect linkage via one or more bifunctional linkers.
• Preferred linkers are those that are biodegradable, non-toxic when cleaved from the conjugate, and are relatively stable to hydrolysis in the circulation.
• taxanes are diterpenes produced by the plants of the genus Taxus (yews), and are widely used as chemotherapy agents.
• the at least one PEG is poly(ethylene glycol) methyl ether (mPEG) having an average M n of between about 550 and about 10,000, preferably about 2000.
• the CMC consists of between about 95 and 3600 monomer units, preferably about 3500 monomer units.
• the molar ratio of (CMC-Ac acetyl groups): (CMC-Ac carboxylic acid groups/PEG/hydrophobic drug) is between about 2.5:0.5 - 1.8: 1.2, preferably about 2.18 : 0.82.
• the mPEG is present in an amount of about 3.5-24.6 weight %, and the taxane is present in an amount of about 22.5-43.9 weight %, further preferably, in PEG is present in the amount of 4.7 - 5.3 weight%, and the taxane is present in an amount of about 30.1 -39.5 weight %, and further preferably, PEG is present in an amount of 4.7 weight %, and the taxane is present in an amount of 36.9 weight %.
• the molar ratio of mPEG: taxane: (CMC-Ac carboxylic acid groups) is from about 0.9 : 4.4 : 94.7 to about 5.4 : 26.4 : 68.2, as estimated by ⁇ NMR analysis, preferably from about 1 : 13.4 : 85.6 to about 2.0 : 22.1 : 75.9, further preferably 1.8 : 13.4 : 84.8.
• the molar ratio of mPEG:cabazitaxel:(CMC-Ac carboxylic acid groups) is about 1.8 : 13.4 : 84.8.
• the molar ratio of mPEG:larotaxel:(CMC-Ac carboxylic acid groups) is about 6.2 : 45.9 : 47.9.
• the CMC-Ac is further covalently linked to at least one imaging agent, preferably Cy5.5.
• a self-assembling nanoparticle composition comprising the compound described herein.
• the composition has a critical micelle concentration (cmc) of about 0.1 mg/mL.
• the self-assembling nanoparticle composition described herein further comprising at least one hydrophobic agent encapsulated therein, preferably selected from either an imaging agent or a therapeutic agent.
• the at least one imaging agent is a superparamagnetic iron oxide nanoparticle (SPION), preferably between 7-30 weight % SPION, and more preferably about 30 weight % SPION.
• SPION superparamagnetic iron oxide nanoparticle
• a pharmaceutical composition comprising the self- assembling nanoparticle composition described herein and a pharmaceutically acceptable carrier and/or diluent.
• a method for providing sustained-release delivery of a hydrophobic drug to a patient in need thereof comprising administering to the patient an effective amount of the self-assembling nanoparticle composition as described.
• a method of treating cancer in a patient in need thereof comprising administering to said patient an effective amount of a self-assembling nanoparticle composition comprising the compound described herein.
• the cancer is selected from breast cancer, lung cancer, metastatic cancer, and pancreatic cancer.
• a process for preparing a self-assembling nanoparticle composition comprising: a) covalently linking at least one PEG and at least one hydrophobic drug, comprising a taxane, preferably cabazitaxel or larotaxel, to a CMC-Ac; b) isolating the product of step (a); c) dissolving the isolated product of step (b) in a suitable organic solvent, preferably DMF or DMSO and further preferably THF or acetonitrile, to form a solution; d) adding the solution of step (c) dropwise to an aqueous solution or by a nanoprecipitation process under conditions suitable for forming the self- assembling nanoparticle composition.
• a suitable organic solvent preferably DMF or DMSO and further preferably THF or acetonitrile
• the covalent linkages are ester linkages.
• Suitable solvents for use in the processes of the present invention include those solvents that are inert under the conditions of the reaction/procedure being described in conjunction therewith.
• said suitable conditions in step (d) comprise vigorously mixing said aqueous solution during the dropwise addition of the solution of step (c).
• the solution of step (c) has a concentration of 10-25 mg/mL.
• the solution of step (c) has a concentration of 10 mg/mL.
• step (d) comprises a 10-fold dilution of the solution of step (c) once the addition to the aqueous solution is complete.
• the aqueous solution of step (d) is selected from 0.9% NaCl, 10% sucrose, or water.
• the organic solvent in step (c) is selected from acetonitrile (CH 3 CN) or tetrahydrofuran (THF), preferably CH 3 CN.
• step (b) comprises precipitation of the product of step (a) using ether, and washing the precipitate with water.
• the process further comprises isolating the self-assembling nanoparticle composition formed in step (d) via dialysis and/or filtration.
• the CMC-Ac is prepared via acetylation of a carboxymethyl cellulose with a degree of substitution (DS) of between about 0.75 and about 0.85, preferably about 0.82.
• the at least one PEG is poly(ethylene glycol) methyl ether (mPEG) having an average M n of between about 550 and about 10,000, preferably about 2000.
• step (a) comprises providing the mPEG in an amount of about 30 mol % and providing the taxane in an amount of about 40-50 mol %, relative to the carboxylic acid groups of said CMC -Ac, preferably about 40 mol% or 50 mol%.
• the solution of step (c) further comprises at least one hydrophobic agent encapsulated therein, preferably selected from either an imaging agent or a therapeutic agent.
• the at least one imaging agent is a superparamagnetic iron oxide nanoparticle (SPION).
• the organic solvent in step (c) is THF.
• the at least one imaging agent is present in the solution of step (c) in an amount of about 9-50 weight %, based on the combined weight of the at least one imaging agent and the isolated product of step (b).
• Ro, Ri ( i)...Ri( n ), R 2 (i)...R 2 ( n ), R3(i)-R3(n), and Re nd are each independently selected from:
• -O(HD) represents a hydrophobic drug, comprising a taxane, preferably cabazitaxel or larotaxel, having a point of attachment via a hydroxyl group; or n is an integer > 94.
• the ratio of (a):(b+c+d) is about 2.18 : 0.82.
• n is between about 95 and 3600 monomer units, preferably about 3500.
• Docetaxel was purchased from LC Laboratories (Woburn, MA, USA). Slide-a-Lyzer 10 and 20 kDa MWCO dialysis cartridges were purchased from Pierce Biotechnology (Rockford, IL). Vivaspin 10 kDa MWCO ultracentrifugation filters were purchased from Fisher (Ottawa, ON, Canada).
• DTX analysis was performed on an HPLC system consisting of a Waters e2696 Separation Module, 2414 RI and 2998 PDA detectors, and operated by Empower Pro 2 software.
• the samples were injected onto an Agilent XDB-C18 column (1.8 ⁇ , 4.6 x 50 mm) column with 0.35 mL/min 95/5 acetonitrile/water isocratic program.
• the method for analysis and detection of taxanes was derived from several published reports, 69"71 adapted for the instrumentation in the lab.
• known taxane identities docetaxel, paclitaxel, and 7-epidocetaxel
• samples were analyzed by a Waters Acquity UPLC/MS system equipped with a PDA and SQ MS detector.
• samples were injected on an Acquity UPLC BEH CI 8 column (1.7 ⁇ , 2.1 x 50 mm), at a flowrate of 0.4 mL/min, with a gradient program of 95-10% water/acetonitrile over 5 minutes.
• Detection of DTX (and other products) were in ES+ mode.
• Polymers were analyzed by a GPC system consisting of a Waters e2696 Separation Module, 2414 RI and 2998 PDA detectors, and operated by Empower Pro 2 software.
• THF soluble samples were injected onto Waters Styragel HR5E and HR 3 columns (in series) with 0.35 mL/min THF flowrate. Water soluble samples were analyzed using a Waters Ultrahydrogel 1000 column with a 1 mL/min flowrate of water. Detection of free DTX and PEG was by PDA (274 nm) and RI respectively.
• CMC-Na CEKOL 30K Sodium carboxymethylcellulose
• the slurry of CMC-COOH powder was washed with water until the water tested neutral, and then washed with 3 x 30 mL glacial acetic acid volume to ensure complete dehydration of the CMC-COOH.
• the CMC-COOH was transferred to a round bottom flask placed in an ice bath, and suspended in glacial acid (50 mL).
• mPEG-OH (690 mg, 0.35 mmol) was dissolved in MeCN (2 mL) with mild heating.
• DTX (465 mg, 0.58 mmol) was dissolved in MeCN (12 mL) and DMF (1 mL).
• the EDC HCL, NHS, and DMAP reagents were added to the CMC -Ac solution, followed by addition of the mPEG-OH and the DTX.
• the solution was stirred overnight at room temperature with protection from light.
• the solvent was removed by rotary evaporation (55°C, 5 mbar), and the product (Cellax-DTX) was dissolved in MeCN (3 mL), and precipitated through 40 mL diethyl ether.
• the Cellax was dried, re-dissolved in MeCN, and the precipitation was repeated 2X. The solvent was removed by heavy vacuum, and the fine powder was washed with water (25 mL) and recovered by centrifugation. The Cellax-DTX product was analyzed by gel permeation chromatography for un-reacted PEG and DTX, and washing was repeated if residual reagent was detected. H NMR analysis (CDCI 3 ) was conducted to confirm the presence of DTX and PEG, and to estimate molecular composition. The feed ratio of DTX was varied while holding PEG constant to create a range of DTX content Cellax-DTX models.
• CMC-Ac 50 mg, 0.19 mmol acid
• EDC HC1 75 mg, 0.39 mmol
• NHS 45 mg, 0.39 mmol
• DMAP 5 mg, 0.04 mmol
• varied DTX 16, 31 , 47, 63, 142 mg, 0.02, 0.04, 0.06, 0.08, 0.18, mmol
• mPEG- OH 117 mg, 0.06 mmol
• CMC -Ac 100 mg, 0.39 mmol acid
• EDC HC1 224 mg, 1.17 mmol
• NHS 135 mg, 1.17 mmol
• DMAP 48 mg, 0.39 mmol
• PEG 78, 156, 390, 546, 780, 1 169 mg, 0.04, 0.08, 0.19, 0.27, 0.39, 0.58 mmol
• DTX 157 mg, 0.19 mmol
• a CMC-Ac-PEG control molecule was synthesized using the same conditions as described for Cellax-DTX.
• CMC-Ac 100 mg, 0.38 mmol acid
• mPEG 2 ooo 230 mg, 0.12 mmol
• EDC HC1 147 mg, 0.77 mmol
• NHS 88 mg, 0.77 mmol
• DMAP 9 mg, 0.08 mmol
• the solvent was removed by rotary evaporation (55°C, 5 mbar), dissolved in water (5mL) and dialyzed against multiple exchanges of water using 20kDa MWCO Slide-a-lyzer dialysis cartridges.
• the purified product was recovered by lyophylization, and analyzed by aqueous GPC to verify that un-reacted PEG had been entirely extracted. Analysis of chemical composition was performed by 'H NMR in D 2 0. Conjugation of DTX, Cy5.5, and PEG to CMC
• Superparamagnetic iron oxide nanoparticles were prepared according to the method published by Sun. 73 Iron(III) acetylacetonate (353 mg, 1 mmol) was mixed with 1 ,2-hexadecanediol (1292 mg, 5 mmol), oleic acid ( 1224 mg, 4.3 mmol), oleic amine (1214 mg, 4.5 mmol) and diphenylether (10 mL) in a 37°C water bath, and stirred under nitrogen. The vial was heated to 200°C on a heating block, with occasional mixing. The reaction mixture was cooled to room temperature, the nitrogen atmosphere was flushed, and the solution was heated to 265°C, and refluxed for 30 minutes under nitrogen protection.
• SPIONs Superparamagnetic iron oxide nanoparticles
• the solution was cooled to room temperature. Isopropanol (20 mL) was added to the reaction system, and the particles were recovered by centrifugation (2500 rpm, 5 min). Hexane (1 mL) was added to dissolve the compound, and the solution was centrifuged at 2500 rpm for 5 minutes. The SPIONs were dried, weighed, and hexane was added to bring the concentration up to 10 mg/mL.
• the DTX content in the Cellax polymer was estimated by HPLC analysis of hydrolyzed polymer samples: Cellax-DTX (2 mg) was dissolved in acetonitrile (1 mL) and treated with 8.5% ortho-phosphoric acid (0.3 mL) for 30 seconds on a vortexer. Samples were immediately extracted with ethyl acetate (3 mL). Water was added to each sample (3 mL) in a 15 mL conical tube, and the tube was centrifuged for 5 minutes at 3000 rpm to separate the organic and aqueous layers. The ethyl acetate fraction was isolated, dried by rotary evaporation, and acetonitrile (0.5 mL) was added to dissolve the sample for HPLC analysis.
• Cellax-DTX 250 mg was dissolved in acetonitrile (25 mL) without heating. Particles were prepared in batches: 0.2 mL Cellax-DTX solution was added dropwise to a vortexing solution of 1.9 mL 0.9% NaCl solution in a 15 mL conical tube. Vortexing was maintained for 1 minute after solution addition. The resulting particle solutions were combined and transferred to a Slide-a-lyzer 10 000 MWCO cartridge, and dialyzed against 0.9% NaCl for three hours, with two exchanges of dialysate.
• the particles were filtered through a 0.22 um 25 mm Millipore PVDF filter, and transferred to a Vivaspin centrifugal filter unit (25 mL, 10 000 MWCO), and spun at 3000 rpm for 1 hour to concentrate the particles to a 1 mL volume.
• the size of the particles was determined by dynamic light scattering with a particle analyzer (Zetasizer Nano-ZS, Malvern Instruments Ltd, Malvern, UK).
• DTX content of the conjugates was determined by diluting the sample 10X in D DMSO, and performing proton NMR measurements of DTX with 2-methyl-5-nitrobenzoic acid as an internal standard.
• Cy5.5-Cellax and Cellax-DTX were prepared for in vivo studies, and the particle preparation was optimized by testing a range of ratios.
• Cellax-DTX 100 uL, 10 mg/mL in acetonitrile
• Cy5.5 Cellax 2, 5, 10, 15 and 30 uL, 10 mg/mL in acetonitrile
• Each solution was precipitated into 0.9% saline (0.9 mL), filtered through a 0.22 um 25 mm Millipore PVDF filter, and particle size was measured by a Zetasizer.
• Cellax-CBZ nanoparticles were prepared in a controlled nanoprecipitation process by hydrodynamic flow focusing through a two-channel microfluidic system (NanoAssemblr, Precision Nanosystems, Canada).
• Cellax-CBZ polymer 150 mg was dissolved in acetonitrile at varying concentrations (4-45 mg/mL), fed through one channel and 0.9% NaCl fed through the adjacent channel.
• Total flow rate was maintained at 12-24 mL/min and the flow ratio of the aqueous to organic stream was 2: 1 to 4: 1.
• the optimal conditions were typically 30 mg/mL polymer in acetonitrile, 18 mL/min flow, and a 3: 1 organic: saline ratio.
• Nanoprecipitation generally involves the formation of nanoparticles by precipitation of a water insoluble polymer dissolved in a water miscible organic solvent upon addition to water. Workable variations to the above described nanoprecipitation process would be known to a person skilled in the art.
• the method for determination of the critical micelle concentration was adapted from Zhang, and consists of a fluorescence-based analysis.
• 67, 74 l ,6-diphenyl-l,3,5-hextriene (DPH, 1.175 mg) was dissolved in acetonitrile (10 mL) to form a stock solution.
• Cellax-DTX (10 mg) was dissolved in 1 mL of the DPH stock solution to form a 10 mg/mL solution, and was serially diluted with the DPH solution to form a series of 10 concentrations of Cellax-DTX in a constant concentration of DPH. 100 ⁇ . volumes of each sample were precipitated drop-wise in 900 uL 0.9% NaCl on a vortexer for 1 minute.
• Cellax-DTX particles were assayed for DTX content, the solution was adjusted to 500 ug DTX / mL, and was sterile filtered through Millipore PVDF 0.22 ⁇ filters. A paclitaxel internal standard was added (5 ug PTX / mL) to the particle solution. Equal volumes of particle solution and fetal bovine serum (FBS) were combined under asceptic conditions, and incubated at 37°C. At selected timepoints (1 , 2, 3, 4, 7 and 14 days) 1 mL volumes were taken and combined with 3 mL ethyl acetate, the samples were mixed well for 30 minutes, and then centrifuged at 4000 rpm for 5 minutes to separate the layers.
• FBS fetal bovine serum
• PC3 prostate cancer cells MDA-MB-231 mammary carcinoma cell, EMT-6 murine mammary carcinoma cells and LL/2 murine Lewis lung cell carcinoma cells were cultured in DMEM media (Invitrogen) with high glucose, supplemented with 10% FBS (Invitrogen), penicillin (100 U/ml) and streptomycin (100 ⁇ g/m]) (Invitrogen).
• the mouse mammary carcinoma cell line EMT-6 was a generous gift from Dr. David Stojdl at the CHEO Research Institute and Dr. Douglas Mahoney at the University of Ottawa.
• DTX solutions were made up in DMSO and diluted with media to form a 100 nM stock solution with 0.1% DMSO content. These DTX samples were 2X serially diluted with 0.1% DMSO media. Cellax particles were assayed for taxane content, and 10X serially diluted with media.
• the cultures were maintained for three days, at which time cell viability was assayed by the XTT assay. Briefly, a 1 mg/mL solution of XTT reagent (Sigma) in water was prepared, and phenazine (Sigma) was added just before analysis (x mg/mL). The culture plates were incubated for two hours at 37°C, and absorbance of each well at 480 nm was then read. Wells treated with media (or 0.1% DMSO media) represent 100%) viable cultures, and wells containing no cells represent background signal. In a parallel experiment, the taxane or Cellax-DTX -containing media were added to the cultures in four steps, with addition of 1 ⁇ 4 the dose every 12 hours for two days. The data was analyzed in GraphPad Prism, and the IC50 for each system was calculated. Animal Studies
• mice Female BALB/c and C57/BL6 mice (aged 6 weeks, 18-20 g) were purchased from The Jackson Laboratory (Bar Harbor, ME). NOD-SCID mice were purchased from the OICR stemcell colony (Toronto, ON). All experimental protocols in this study were approved by the Animal Care Committee of the University Health Network (Toronto, Ontario, Canada) in accordance with the policies established in the Guide to the Care and Use of Experimental Animals prepared by the Canadian Council of Animal Care. For each study, the DTX was formulated in a Tween80/ethanol/saline (20: 13:67) solution (4 mg DTX/mL), and sterile filtered. The Cellax particles were adjusted desired dose (mg taxane/mL) in saline and sterile filtered.
• mice Tissues from mice (organs, bones, and tumors) were rinsed with saline and fixed in 10% formalin for 2 days, followed by storage in 70% ethanol. Preparation of tissues into slides was performed at the Toronto General Hospital Pathology Research Program lab (Toronto, ON). Ki67 (SP6) antibody (ThermoFisher) was used at a 1/1000 dilution in citrate for 1 hour. CD31 (PECAM) antibody (Santa Cruz) was used at 1/2000 dilution in Tris-EDTA buffer, pH 9 for 1 hour. TUNEL staining was performed according to the method of Wijsman 75 .
• Healthy BALB/c mice were treated with free DTX at 20 and 40 mg/kg doses, by 200 uL i.v. tail vein injection. Likewise, healthy BALB/c mice were treated with Cellax- DTX at 20, 40, 85, and 170 mg/kg DTX equivalent doses. Control mice received injections of Tween80/ethanol/saline or saline. Body weight was monitored for 7 days, and upon sacrifice, organs were harvested for histological and immunohistochemical analysis. Blood was collected, and serum and whole blood were analyzed for serological and hematological parameters, referenced against control blood samples.
• EMT-6 cells were cultured as described previously. Prior to inoculation, the cells were lifted from the culture plates with TrypLE Express, and re-suspended in supplement free (no FBS, no antibiotics) DMEM media. The EMT-6 cells (2 x 10 5 cells/50 ⁇ medium) were s.c. inoculated into the shaved right lateral flank of BALB/c mice. After 7 days, when the tumors became palpable, the mice received 40 mg/kg doses of DTX and Cellax-DTX, as described in the MTD study. Control animals received saline injections. Each group (DTX, Cellax-DTX, and control) was comprised of six mice.
• the tumor size was measured by a caliper, and body weight was monitored. After 14 days the mice were sacrificed by cervical dislocation, and the heart, lung, liver, kidneys, and tumor were collected for tissue sectioning and staining with H&E, TU EL, Ki67, and CD31.
• a second study (similar to the EMT-6 study) was performed with LL/2 cells s.c. inoculated into C57/BL6 mice: the LL/2 cells were suspended in supplement free DMEM media. Further studies were performed with PC3 cells (parent line) and DTX-resistant PC3 cells (resistant line) in a male NOD- SCID mouse model. Mice bearing PC3 tumors were treated with CBZ and Cellax- CBZ and tumor size was monitored.
• Healthy BALB/c mice received an i.v. dose of EMT-6 cells (in supplement free DMEM media) via tail vein injection (50 uL, 2.5x10 5 cell/mL), and one day following received a dose of Cellax-DTX (40 mg DTX/kg), 40 mg/kg DTX, or saline (n 10 / group). A second dose (20 mg/kg DTX) was administered on day 7 post-cell injection. Mice were sacrificed when >20% body weight loss was recorded, or at the first signs of behavioral or mobility dysfunction. The lungs, heart, liver, kidneys, spleen, femurs, and brain were harvested for histological analysis. A Kaplan Meier plot of survival probability was generated from the survival data.
• PAN02 cells (murine pancreatic cancer) were cultured in RPMI 1640 supplemented with 10% FBS (Invitrogen), penicillin (100 U/ml) and streptomycin (100 ⁇ / ⁇ 1) (Invitrogen), and pyruvate (1 mM). Prior to inoculation, the cells were lifted from the culture plates with TrypLE Express (Invitrogen), and re-suspended in supplement free (no FBS, no antibiotics) RPMI media. The PAN02 cells (5 x 10 6 cells/mL, 0.5 mL) were injected into the intraperitoneal space of C57/BL6 mice.
• VOI volume of interest
• Sections of adjacent muscle tissue were likewise delineated with a VOL Hypointense tumor voxels were defined as tumor voxel intensity minus 5X the standard deviation of mean muscle voxel intensity.
• a hypointense volume was calculated.
• the volume fraction of each tumor containing hypointense voxels was calculated as non-threshold volume / threshold volume.
• CMC-Ac Acetylated carboxymethylcellulose
• CMC-Ac Acetylated carboxymethylcellulose (CMC-Ac, 50 mg, 0.19 mmol acid) was weighed into a 25 mL glass vial, and dissolved in MeCN (0.5 mL).
• EDC HC1 (1 12 mg, 0.58 mmol) was dissolved in MeCN (3 mL) and water (0.1 mL).
• NHS 67 mg, 0.58 mmol
• DMAP 24 mg, 0.19 mmol
• MeCN mL
• mPEG-OH (1 17 mg, 0.06 mmol) was dissolved in MeCN (1 mL) with mild heating.
• PTX 67 mg, 0.08 mmol was dissolved in MeCN (2 mL) and DMF (0.2 mL).
• the EDC HCL, NHS, and DMAP reagents were added to the CMC-Ac solution, followed by addition of the mPEG-OH and the PTX. Reaction purification was identical to that of the DTX conjugate. Composition was confirmed by H NMR (41 weight% PTX, 5.7 wt% PEG). Particles were isolated with a size of 1 15 nm and a PDI of 0.1.
• CMC-Ac Acetylated carboxymethylcellulose (CMC-Ac, 100 mg, 0.38 mmol acid) was weighed into a 25 mL glass vial, and dissolved in DMF (4 mL). DCC (158 mg, 0.76 mmol) and DMAP (9 mg, 0.08 mmol) were dissolved in DMF (0.5 mL). mPEG-OH (574 mg, 0.1 1 mmol) was dissolved in DMF (1 mL). DOX (83 mg, 0.15 mmol) was dissolved in DMF (0.25 mL). The DCC and DMAP reagents were added to the CMC-Ac solution, followed by addition of the mPEG-OH and the DOX.
• CMC-Ac Acetylated carboxymethylcellulose (CMC-Ac, 100 mg, 0.38 mmol acid) was weighed into a 25 mL glass vial, and dissolved in MeCN (1 mL).
• EDC HC1 147 mg, 0.76 mmol was dissolved in MeCN (4 mL) and water (0.2 mL).
• NHS 88 mg, 0.76 mmol was dissolved in MeCN (1 mL).
• mPEG-OH 5000 (574 mg, 0.1 1 mmol) was dissolved in MeCN (2 mL) with mild heating.
• DTX 216 mg, 0.27 mmol was dissolved in MeCN (4 mL).
• the EDC and NHS reagents were added to the CMC- Ac solution, followed by addition of the mPEG-OH and the DTX. Purification of the product was identical to that of Cellax-DTX synthesized with mPEG-OH 2000.
• DTX (157 mg, 0.19 mmol) was dissolved in MeCN (4 mL) and DMF (0.3 mL).
• the EDC HCL, NHS, and DMAP reagents were added to the CMC-Ac solution, followed by addition of the mPEG-OH and the DTX. Purification of the product is identical to that described for process described for the CEKOL 30K CMC-Ac analogue. Particles were isolated from this preparation with a size of 140 nm.
• Cellax-DTX particles were diluted 100X in deionized water, and a 2 ⁇ iL aliquot of solution was pipetted onto the surface of formvar coated copper TEM grids (TedPella, Redding, CA) and allowed to air dry. Analysis was performed on an Hitachi HD-2000 STEM at the Centre for Nanostructure Imaging (Department of Chemistry, University of Toronto), using a high angle annular dark field detector, with an activation voltage of 200 kV and a current of 10 mA. TEM analysis of the particles supports the Zetasizer measurement (104 +/- 15 nm), and as seen in Figure Example 6, the particles are spherical.
• CMT camptothecin
• CMC- Ac acetylated carboxymethylcellulose
• Composition was confirmed by 1H NMR (50.4 weight% CBZ, 4.63 wt% PEG). Particles were isolated with a size of 1 12 nm and a PDI of 0.17.
• a further series of Cellax-CBZ analogues were prepared by adjusting the feed ratio of PEG (10 to 180%) and CBZ (10-50%) to the CMC polymer, and were purified and analyzed in an identical manner.
• CMC-Ac Acetylated carboxymethylcellulose (CMC-Ac, 25 mg, 0.10 mmol acid) is weighed into a 6 mL glass vial, and dissolved in MeCN (0.2 mL).
• EDC HC1 56 mg, 0.29 mmol
• MeCN 1.5 mL
• water 0.1 mL
• NHS 34 mg, 0.29 mmol
• DMAP (12 mg, 0.10 mmol) are dissolved in MeCN (0.3 mL).
• mPEG-OH 58 mg, 0.03 mmol
• LTX 41 mg, 0.04 mmol is dissolved in MeCN (1.5 mL) and DMF (0.1 mL).
• CMC-Ac was soluble in DMF, but DTX and PEG coupling reactions performed in DMF did not exhibit good yields, and particles formed from these materials were unstable and non-uniform.
• MeCN promoted higher conversions, and subsequently, all conjugation reactions were performed in this solvent.
• 1.5 vol% water was required to dissolve EDC, and 3.0 vol% DMF was required to dissolve the DTX in the MeCN solvent.
• Purification of the polymer by dialysis was initially attempted, but as PEG, DTX, and the CMC reagents possess different solubility profiles, problems with precipitation and low purification efficiency occurred.
• compositions bracketing the functional Cellax-DTX formulation were prepared by varying both PEG and DTX.
• the peak assignments reported above for Cellax-DTX were identical (data not shown), but the integrations of the DTX peaks varied.
• the DS for DTX in functional compositions ranged from 13.4 - 26.4 mol% (22.5 - 43.3 wt%), and the DS for PEG ranged from 0.9-5.4 mol% (3.5-22.7 wt%).
• the preferred composition contained 15.1-23.7 mol% DTX and 1 -1.1 mol% PEG, and the further preferred composition contained 20.5 mol$ DTX and 1 mol% PEG.
• Table 2 Composition comparison between batches of Cellax-DTX conjugates prepared with differing molar composition. N.a. indicates that defined particles could not be detected.
• Cy5.5-Cellax particles were prepared in a protocol similar to that applied to Cellax- DTX particles, except that 1, 5, 10, 15 and 30 wt% of these particles were Cy5.5- Cellax, with the balance made up as Cellax-DTX.
• the particle size measurements were stable at 102-100 nm up to 15 wt% Cy5.5-Cellax, after which the measurements became erratic, possibly due to fluorescence effects in the Zetasizer instrument.
• Cellax-DTX-SPION particles were prepared by precipitating a THF solution of SPION and Cellax-DTX into saline, followed by dialysis and filtration through 0.22 ⁇ filters.
• the size of Cellax-DTX- SPION particles was 1 15.4 nm with a PDI of 0.104, and was readily sterilized through 0.22 ⁇ filters.
• the Cellax-DTX-SPION particles were concentrated by Vivaspin filtration to yield a 1 1.4 mg/mL SPION, 12 mg/mL DTX, 40 mg/mL Cellax-DTX particle solution.
• MR analysis confirmed that Cellax-DTX-SPION particles could provide negative contrast in Tl and T2 modes: as depicted in Figure 3 A, as the solution of particles were diluted from 168 ug SPION/mL downwards, the Tl contrast likewise diminished in a linear relationship.
• the T2 contrast of the SPION particles was high, and when the Cellax-DTX-SPIONS were injected into a mouse (20 mg/kg SPION, 133 mg/kg DTX), excellent contrast in the tumor was detected by T2 and T2* imaging.
• the EMT-6 tumor mass could be seen in the background imaging series ( Figure 3B and 3C), and 3 hours post-injection ( Figure 3D and 3E), the T2 and T2* images shows clear accumulation of SPION. After 24 and 72 hours, these particles remain in residence, moving within the tumor. Image analysis was performed by first defining the tumor volume (VOI).
• hypointense volume fraction increased rapidly at 3 hours (25%), and peaking at 24 hours in both T2 and T2* images at 30%. At 72 hours, the hypointense volume fraction decreased to 15%.
• the Cellax-DTX particles were suspended in a 50:50 mixture of FBS, and DTX release from the particles was monitored over the course of three weeks.
• the FBS was heat-deactivated, and very little DTX release could be detected (data not shown).
• an additional peak was detected in the HPLC analysis, and when the analysis mirrored on a UPLC/MS system, both the DTX peak and the new peak were detected as 808 Da in MS+ mode, indicating that DTX was isomerizing to 7-epidocetaxel.
• the in vitro IC50 analysis of the Cellax-DTX confirmed a cytotoxic effect against both EMT-6 mammary carcinoma and LL/2 lung carcinoma cell lines (Table 4 and Figure 5 A-B).
• the control CMC-PEG polymer mass concentration in cell culture was matched to the mass concentrations of Cellax-DTX, and at no level were there any indications of cytotoxic effects on these cells.
• the EMT-6 cells are more sensitive to the effects of a bolus dose of DTX, exhibiting an IC50 of 80 nM, compared to 767 nM for the LL/2 cells.
• EMT-6 and the LL/2 cell populations were more influenced by the Cellax-DTX particle treatment, with IC50's of 9 and 19 nM, respectively.
• EMT- 6 and LL/2 cultures were also treated with repeated doses of DTX (20 and 200 mM respectively, four applications over two days), to determine if one-doses or metronomic doses of DTX would lead to differing results.
• the viability of EMT-6 and LL/2 cultures were 20 and 12% respectively compared to controls (compared to 50% with a single dose), indicating that sustained exposure to DTX has a more anti-viability effect on these cells.
• mice demonstrated body minor weight loss on administration of the Tween80/ethanol/saline solutions (Figure 6 A).
• Mice treated at 20 mg/kg DTX did not gain or lose weight, but mice at the 40 mg/kg dosing exhibited slightly depressed body weight and mild piloerection.
• mice treated with the Cellax-DTX particles at 20, 40, 85 and 170 mg/kg DTX dosing did not exhibit signs of physical stress, and only the 170 mg/kg Cellax-DTX dosing group exhibited weight loss (Figure 6B).
• the mice in the 170 mg/kg treatment group regained their original body weight within one week of dose administration (Figure 6B). Hematology and blood chemistry analysis did not reveal any abnormalities (Table 5). Histology, and immunohistochemical analysis of the 170 mg/kg mouse organs also did not reveal any abnormalities.
• Table 5 Serological and hematological analysis of blood from Balb/c mice treated with Cellax-DTX (170 mg DTX / kg).
• mice were inoculated with the EMT-6 and LL/2 cells to generate syngeneic tumor models, and these mice were treated a single matched dose of 40 mg/kg DTX or 40 mg eqv/kg Cellax-DTX.
• the free DTX had a minor (not significant) effect on tumour growth compared to the control saline-treated mice.
• a single dose of 40 mg/kg Cellax-DTX had a significant impact on tumor growth (Figure 7A). The study was terminated when the control and DTX- treated mice began to exhibit tumor lesions.
• EMT-6 Model in the H&E stained sections, it was apparent that portions of the Cellax-DTX and DTX treated tumors were necrotic ( Figure 8A), and this observation was mirrored in the Ki67 (cell viability), CD31 (angiogenesis) and TUNEL staining (apoptosis). By visual examination, it was evident that DTX caused necrosis / apoptosis, and this effect was more pronounced within the Cellax-DTX treated tumors.
• the Cellax- DTX treated mice did not exhibit piloerection or parelsis at any point, even when weight loss necessitated sacrifice, suggesting some aspect of cancer (such as chord compression) was absent in the Cellax-DTX- treated mice.
• the median survival times of the control, DTX, and Cellax-DTX groups was 8, 9, and 15 days respectively (Figure 1 IB): Cellax-DTX increased survival time 170% compared to DTX, and 187% compared to untreated mice. Histology analysis of the tissue sections indicated that primary disease burden was in the lungs (Fig 1 1C), with no detectable tumor mass in the heart, liver, spleen, kidneys, brain or bone marrow. By visual inspection, the disease burden in the Cellax-DTX treated mice was less compared to the control and DTX mice.
• One objective of this study was to develop a self-assembling carbohydrate-based therapeutic nanoparticle, and to increase the effectiveness and reduce the toxicity of
• Sodium CMC is a water soluble polymer composed of repeating anhydroglucose units, and is only sparingly soluble in organic solvents such as DMF or DMSO. 79
• the sodium counterion on the carboxylic acid was exchanged with triethylamine (TEA) or tetrabutylammonium (TBA) in order to generate solvent soluble CMC.
• TEA triethylamine
• TSA tetrabutylammonium
• conversion of carboxylic acid groups to DTX and PEG esters using EDC/NHS chemistry was low ( ⁇ 10%), and particles formed using these materials were heterogeneous in size and prone to self-aggregation.
• interest in solvent solubility of CMC has been primarily the domain of chemical and polymer coating companies, where compatibility of the CMC with other resins and the dispersion forming properties of this material were optimized by adjusting solvent
• Namikoshi optimized a chemical process for preparation of carboxyalkyl acetyl celluloses, wherein the sodium salt was converted to a free acid, and the hydroxyl groups were acetylated quantitatively in the presence of acetic anhydride and sulphuric acid catalyst in an acetic acid solvent at 40-60°C. Critical to this reaction was the complete dehydration of the free acid prior to acetylation reactions. Subsequent to this modification, the solvent soluble free acid CMC(Ac) could be rendered water soluble by converting the free acid back to a sodium salt.
• Allen 81 described a similar process for acetylation of the hydroxyl groups, but added sulphuric acid post-acetylation and heated the polymer to partially hydrolyze the acetyl esters and achieve partial water solubility, in order to modulate wetting and gelling properties in coating formulations, and provide for crosslinking site with isocyanates or melamine.
• the inventors noted that subsequent esterification of the carboxyl acid group on each anhydroglucose unit was strongly dependant on the carboxylic acid being a free acid.
• the degree of substitution (DS) per anhydroglucose unit was 0.8 mol acid per mol anhydroglucose, with 2.2 mol hydroxyl (subsequently converted to acetyl groups).
• DS degree of substitution
• ⁇ NMR analysis confirmed the DS calculations: by integration of the proton NMR spectra, the ratio of anhydroglucose protons and acetyl protons was found to conform to prediction.
• Particles prepared in 0.9% sodium chloride, 10% sucrose, or water were stable, and maintained their dimensions when transferred into a 50 vol% solution of FBS.
• the release of DTX from Cellax-DTX nanoparticles was analyzed, to affirm that hydrolysis of the ester bonds would occur in the presence of serum.
• Samples of particles incubated in FBS were extracted with ethyl acetate, and by LC/MS analysis, two peaks with an ES + MS value of 808.8 m/z were detected, corresponding to DTX and a DTX isomer, 7-epidocetaxel: these peaks were analyzed to generate a total taxane release value.
• DTX is an anti-mitotic antineoplastic drug which binds to tubulin and impedes cell replication, ultimately inducing apoptosis and cell death. Cells surviving the initial exposure to DTX can continue to replicate in the absence of subsequent DTX administration.
• DTX-PoLi ge i chitosan/laurinaldehyde/egg phosphatidylcholine/DTX gel
• DTX-PoLi ge i chitosan/laurinaldehyde/egg phosphatidylcholine/DTX gel
• mice inoculated with PAN02 cells (and not treated) exhibited signs of disease five days post-inoculation ( Figure 12), and experienced rapid decline. Treatment with 120 mg/kg gemcitabine did not confer significantly increased benefits to the mice. Conversely, mice treated with DTX and Cellax-DTX (40 mg/kg) did not present with symptoms for longer periods, and survival was significantly extended.
• the Cellax-DTX particles increase the MTD for docetaxel in mice models to > 170 mg/kg compared to 40 mg/kg for free DTX, and are more effective that DTX against murine breast and lung cancer lines in vivo.
• a one- dose treatment of 40 mg/kg Cellax-DTX effectively minimized the growth of murine EMT-6 and LL/2 flank tumors: immunohistochemical and histology analysis indicating increased apoptosis in Cellax-DTX treated tumors, and reduced microvessel formation and cell replication.
• Cellax-DTX was particularly effective against a metastatic breast cancer model in Balb/c mice, and further studies will investigate the mechanism by which Cellax-DTX doubled survival time and reduced clinical symptoms of bone metastases and chord compression.
• Camptothecin-PEG-CMC illustrates that very hydrophobic drugs can be successfully conjugated to CMC-Ac, enabling the delivery of otherwise insoluble drug.
• a different synthetic and purification scheme was used than for DTX, tailored to this compound's specific chemistry and solubility.
• Paclitaxel and docetaxel are both commonly used anticancer drugs, and preparation of PTX and DTX analogues had equivalent synthetic and purification processes.
• CMC is available in a range of MW's, but are characterized principally by viscosity and degree of substitution due to difficulties in analyzing MW, as would be understood by a person skilled in the art.
• a variant produced with CMC (MW 20000) produced a particle of 140 nm.
• Example 8 Cabazitaxel and Larotaxel Particles
• Cabazitaxel (CBZ) and larotaxel (LTX) are chemically similar to docetaxel: the preparation of CBZ and LTX analogues had equivalent synthetic and purification processes to the DTX formulation. Further, these compounds produced nanoparticles smaller than 200 nm, representing functional drug delivery vehicles.
• Cellax-CBZ polymers were prepared with a range of composition (varying CBZ and PEG content) and a range of particles were generated using the NanoAssemblr using 30 mg/mL polymer, a 3: 1 feed ratio of solvent: saline, and 18 mL/min flow (Table 7). As with the Cellax-DTX examples, a range of functional composition was defined, outside of which poorly defined particle formation was identified. Selected examples of Cellax-CBZ polymer were analyzed for in vitro cytotoxicity in the PC3 and MDA-MB- 231 cell lines (Table 8), and exhibited an improved cytotoxicity with respect to native CBZ.
• Table 7 Composition comparison between batches of Cellax-CBZ conjugates prepared with differing molar composition
• NOD-SCID mice bearing either PC3 (prostate, parent line) or DTX-resistant PC3 (prostate, resistant line) were treated with CBZ (10 mg CBZ/kg) or Cellax-CBZ (85 mg CBZ/kg).
• PC3 tumors exhibited treated with CBZ exhibited partial tumor growth inhibition, but eventually regressed ( Figure 13).
• Tumors treated with Cellax-CBZ exhibited complete remission which was sustained at 125 days post-treatment.
• DTX- resistant PC3 tumors treated with CBZ (10 mg CBZ/kg) exhibited no tumor inhibition, whereas Cellax-CBZ treated mice exhibited a significant response.
• Facchini A Segatti F, inventors; LIMA Lto SpA, assignee. N-methyl-amine derivitives of Carboxymethylcellulose, alginic acid N-methyl-amide or carboxymethyl starch. 2005.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49996459

Family Applications (1)

Country Status (1)

Cited By (35)

Citations (6)

• 2013
  • 2013-07-26 WO PCT/CA2013/000674 patent/WO2014015422A1/fr not_active Ceased

Patent Citations (6)

Non-Patent Citations (6)

Similar Documents

Legal Events